BEDMINSTER, N.J. and DUBLIN, Ireland, May 24, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN - News), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that additional data from the AMR101 pivotal Phase 3 studies (MARINE and ANCHOR) will be presented along with an encore presentation of the ANCHOR study by Harold E. Bays M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center,at the National Lipid Association (NLA) 2012 Annual Scientific Sessions in Scottsdale, Ariz., on May 31- June 3.
